AbbVie could use a win. The pharma giant, already facing nosediving sales of its flagship immunology drug Humira, also suffered two mid-stage schizophrenia flops last week. The setback erased more than $40 billion from AbbVie’s market cap.

Does the company have another trick up its sleeve? Cantor Fitzgerald analyst Louise Chen called AbbVie’s pipeline “underappreciated,” in a recent note. And already, the company is making progress — AbbVie yesterday announced its ovarian cancer treatment Elahere gained European approval, adding to a full U.S. go-ahead earlier in the year. And schizophrenia wasn’t the end of the road for AbbVie in neuroscience as two more candidates from its $9 billion Cerevel purchase wait in the wings: the late-stage tavapadon in Parkinson’s disease and an epilepsy and anxiety drug called darigabat. “All is not lost with the Cerevel acquisition,” Chen said.

There’s even more on the horizon as AbbVie invests in not only the assets within its pipeline but also the inner workings of its R&D machine. Today, we’re featuring a conversation with AbbVie’s “head of R&D cures” about the way the company approaches next-generation drugs that delve into the territory of curative medicine.

Thanks for reading.